SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
AYTU reported Q1 fiscal 2027 results. The price and volatility reaction is pending.
AYTUearnings

Earnings reactions

Aytu BioPharma, Inc. (AYTU) Q1 FY2027 earnings

November 17, 2026 · SharpeIQ Research Desk

Reported results

  • Net revenue was $14.8 million for the first quarter of fiscal 2027, compared to $13.9 million for the prior-year period (GAAP).
  • EXXUA net revenue was $4.9 million for the first quarter of fiscal 2027 (GAAP).
  • ADHD Portfolio net revenue was $7.7 million for the first quarter of fiscal 2027, compared to $13.2 million in the prior-year period (GAAP).
  • Pediatric Portfolio net revenue was $2.2 million for the first quarter of fiscal 2027, compared to $0.7 million in the prior-year period (GAAP).
  • Net loss was ($3.9) million for the first quarter of fiscal 2027, compared to net income of $2.0 million in the prior-year period (GAAP).
  • Adjusted EBITDA was ($2.6) million for the first quarter of fiscal 2027, compared to ($0.6) million in the prior-year period (non-GAAP).

Notes

The Company entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. on November 16, 2026, for $2.70 per share in cash.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →